Dogwood Therapeutics (DWTX) Other Accumulated Expenses (2020 - 2026)
Dogwood Therapeutics (DWTX) posted quarterly Other Accumulated Expenses of $22693.0 for Q1 2026, up 155.67% year-over-year from $8876.0 in Q1 2025, and down 13.53% quarter-over-quarter from $26244.0 in Q4 2025.
Dogwood Therapeutics (DWTX) Other Accumulated Expenses (2020 - 2026) Analysis & Trends
Dogwood Therapeutics (DWTX) has reported Other Accumulated Expenses for 7 consecutive years, with $22693.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Accumulated Expenses rose 155.67% year-over-year to $22693.0; the TTM figure through Mar 2026 stood at $22693.0 (up 155.67% YoY), while the FY2025 annual figure was $26244.0, up 2228.66% from the prior year.
- Other Accumulated Expenses eased to $22693.0 in Q1 2026 per DWTX's latest filing, from $26244.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $26704.0 in Q2 2025 and bottomed at $225.0 in Q2 2024.
- Historically, Other Accumulated Expenses has averaged $10773.6 across 5 years, with a median of $7308.5 in 2023.
- Annual changes were most pronounced in 2024 — Other Accumulated Expenses sank 95.63% — and 2025, when it jumped 11768.44%.
- Dogwood Therapeutics' Other Accumulated Expenses stood at $1360.0 in 2022, then soared by 322.13% to $5741.0 in 2023, then sank by 80.37% to $1127.0 in 2024, then soared by 2228.66% to $26244.0 in 2025, then retreated by 13.53% to $22693.0 in 2026.
- Business Quant data shows DWTX's Other Accumulated Expenses at $22693.0 in Q1 2026, $26244.0 in Q4 2025, and $19559.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Dogwood Therapeutics | 84.98 Mn | 84.98 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 22,693.00 |
| Dec 31, 2025 | 26,244.00 |
| Sep 30, 2025 | 19,559.00 |
| Jun 30, 2025 | 26,704.00 |
| Mar 31, 2025 | 8,876.00 |
| Dec 31, 2024 | 1,127.00 |
| Jun 30, 2024 | 225.00 |
| Sep 30, 2023 | 5,741.00 |
| Jun 30, 2023 | 5,150.00 |
| Mar 31, 2023 | 2,662.00 |
| Dec 31, 2022 | 1,360.00 |
| Sep 30, 2022 | 5,498.00 |
| Jun 30, 2022 | 12,491.00 |
| Mar 31, 2022 | 12,500.00 |
| Dec 31, 2021 | 7,375.00 |
| Sep 30, 2021 | 16,332.00 |
| Jun 30, 2021 | 15,050.00 |
| Mar 31, 2021 | 93,432.00 |
| Dec 31, 2020 | 13,548.00 |